Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.23% is 78% below its 5-year average of 14.56%, near the low end of its 5-year range (0.12%–32.02%).
As of the fiscal period ended Tuesday, March 31, 2026. 17.07% below its 12-month average of 3.89%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2026 (2026-03-31): 3.23%.
DEBT TO ASSETS RATIO
3.23%
DEBT TO ASSETS RATIO AVG TTM
3.89%
DEBT TO ASSETS RATIO AVG 3Y
14.38%
DEBT TO ASSETS RATIO AVG 5Y
14.56%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-17.07%
CURRENT VS 3Y AVG
-77.56%
CURRENT VS 5Y AVG
-77.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+3483.82%
vs the sector median at left
China SXT Pharmaceuticals, Inc.
Market Cap
$667469.00
Debt to Assets Ratio
3.23%
TTM Avg
3.89%
3Y Avg
14.38%
5Y Avg
14.56%
Market Cap
$545796.00
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$518606.00
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$824550.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$838843.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$481786.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$868077.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| China SXT Pharmaceuticals, Inc. (SXTC) | $667469.00 | 3.23% | 3.89% | 14.38% | 14.56% |
| CDT Equity Inc. (CDT)vs › | $716854.00 | 0.38% | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | 0.25% | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | 0.08% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | 0.00% | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | 0.00% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | 0.01% | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | 0.00% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | 0.00% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | 0.01% | N/A | N/A | N/A |
Debt/Assets
3.2%
Debt/Equity
0.04
Current Ratio
7.93
Interest Coverage
-113.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-03-31 | 3.23% |
| 2025-12-31 | 3.23% |
| 2025-09-30 | 4.57% |
| 2025-03-31 | 4.54% |
| 2024-12-31 | 4.54% |
| 2024-09-30 | 31.85% |
| 2024-06-30 | 31.85% |
| 2024-03-31 | 11.45% |
| 2023-12-31 | 15.98% |
| 2023-09-30 | 24.10% |
| 2023-06-30 | 24.49% |
| 2023-03-31 | 12.71% |
| 2022-12-31 | 30.32% |
| 2022-09-30 | 5.44% |
| 2022-06-30 | 7.10% |
| 2022-03-31 | 32.02% |
| 2021-12-31 | 32.02% |
| 2021-09-30 | 0.12% |
| 2021-06-30 | 11.59% |
| 2021-03-31 | 0.13% |
| 2020-12-31 | 35.29% |
| 2020-09-30 | 0.25% |
| 2020-06-30 | 2.48% |
| 2020-03-31 | 30.98% |
| 2019-12-31 | 30.98% |
| 2019-09-30 | 25.67% |
| 2019-06-30 | 33.63% |
| 2019-03-31 | 15.94% |
| 2018-12-31 | 15.94% |
| 2018-09-30 | 2.42% |
| 2018-06-30 | 4.79% |
| 2018-03-31 | 5.03% |
| 2017-12-31 | 3.75% |
| 2017-03-31 | 5.56% |
